DailyIQ
DailyIQ
MEDPMedpace Holdings, Inc.

Earnings Release

Medpace Holdings, Inc.'s latest earnings press release, filed Oct 21, 2026, scored line by line for tone, guidance and what changed since the prior release.

New outlook issued38 lines scoredFiled Oct 21, 2026SEC 8-K · Exhibit 99
Release Tone
77
UPBEAT
GuidanceNew outlook issuedWhat this release does to the company's outlook
Tone change▲ 1.3pointsvs the prior release (Jul 22, 2026)
Hedging language0.63per 100 words▲ 0.32 vs prior
New this quarter10of 38 linesWording that was not in the prior release

The lines that matter most

Ranked by how material, how strongly worded and how new each sentence is.

  1. 1

    Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million as of September 30, 2025.

  2. 2

    On a constant currency basis, EBITDA for the third quarter of 2026 increased 16.0% from the third quarter of 2025.

  3. 3

    On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025.

  4. 4

    Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period.

  5. 5

    Revenue for the nine months ended September 30, 2026 was $2,129.9 million, and increased 16.9% on a reported basis and 16.7% on a constant currency basis from the comparable prior-year period.

  6. 6

    EBITDA for the third quarter of 2026 increased 16.0% to $172.1 million, or 24.0% of revenue, compared to $148.4 million, or 22.5% of revenue, for the comparable prior-year period.

  7. 7

    This resulted in a net income margin of 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.

  8. 8

    Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.

Release by release

Tone and guidance for the last 3 earnings releases.

  1. Oct 21, 2026New outlook issued76.9+1.3
  2. Jul 22, 2026New outlook issued75.6+1.5
  3. Apr 22, 2026New outlook issued74.1

Bar length: tone on a 50–82 scale.

The release, annotated

1Highlight rankPositive toneNeutralNegative toneDimmed text: low materiality
8Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.
Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6% from net new business awards of $789.6 million for the comparable prior-year period.
Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the comparable prior-year period.
Net income margin was 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.
EBITDA was $172.1 million for the third quarter of 2026, an increase of 16.0% from EBITDA of $148.4 million for the comparable prior-year period, resulting in an EBITDA margin of 24.0%.
CINCINNATI, OHIO, October 21, 2026 -- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results
4Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period.
3On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025.
1Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million as of September 30, 2025.
Net new business awards were $873.4 million, as compared to $789.6 million for the comparable prior-year period.
For the third quarter of 2026, total direct costs were $492.1 million, compared to total direct costs of $463.0 million in the third quarter of 2025.
Selling, general and administrative (SG&A) expenses were $51.8 million in the third quarter of 2026, compared to SG&A expenses of $48.1 million in the third quarter of 2025.
GAAP net income for the third quarter of 2026 was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the third quarter of 2025.
7This resulted in a net income margin of 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.
6EBITDA for the third quarter of 2026 increased 16.0% to $172.1 million, or 24.0% of revenue, compared to $148.4 million, or 22.5% of revenue, for the comparable prior-year period.
2On a constant currency basis, EBITDA for the third quarter of 2026 increased 16.0% from the third quarter of 2025.
Year-to-Date 2026 Financial Results
5Revenue for the nine months ended September 30, 2026 was $2,129.9 million, and increased 16.9% on a reported basis and 16.7% on a constant currency basis from the comparable prior-year period.
Year-to-date 2026 GAAP net income was $382.7 million, or $13.37 per diluted share, compared to $316.0 million, or $10.64 per diluted share, for the comparable prior-year period.
Year-to-date 2026 EBITDA was $474.9 million, or 22.3% of revenue, and increased 19.5% on a reported basis and 20.4% on a constant currency basis from the comparable prior-year period.
Balance Sheet and Liquidity
The Company’s Cash and cash equivalents were $705.3 million at September 30, 2026, and the Company generated $216.6 million in cash flow from operating activities during the third quarter of 2026.
There were no share repurchases in the third quarter of 2026.
As of September 30, 2026, the Company had $527.0 million remaining under its authorized share repurchase program.
Effective October 20, 2026 (“Effective Date”), the Company’s Board of Directors (“Board”) terminated the Company’s current stock repurchase authorization of the Company’s common stock, $0.01 par value (“common stock”) which was set to expire on December 31, 2026.
As of the Effective Date, this repurchase authorization had $527.0 million remaining.
Effective as of the Effective Date, the Board approved a new stock repurchase authorization, pursuant to which the Company is authorized to repurchase up to $1.0 billion shares of common stock until December 31, 2028, at the discretion of the Company’s management.
Repurchases under this new authorization may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to alternative uses of capital, prevailing market conditions, applicable regulatory requirements, and other considerations.
Under the new authorization, any such repurchases may be executed using open market purchases, privately negotiated transactions, transactions in accordance with Rule 10b5-1 of the Exchange Act, or other transactions, and will be funded from cash on hand.
The new authorization does not obligate the Company to acquire any minimum amount of common stock and the new authorization may be modified, limited, extended, suspended or terminated by the Board at any time without prior notice.
2026 Financial Guidance
The Company forecasts 2026 revenue in the range of $2.835 billion to $2.855 billion, representing growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion.
GAAP net income for full year 2026 is forecasted in the range of $514.0 million to $524.0 million.
Additionally, full year 2026 EBITDA is expected in the range of $638.0 million to $652.0 million.
Based on forecasted 2026 revenue of $2.835 billion to $2.855 billion and GAAP net income of $514.0 million to $524.0 million, diluted earnings per share (GAAP) is forecasted in the range of $17.97 to $18.32.
This guidance assumes a full year 2026 tax rate of 19.0% to 19.5%, interest income of $22.9 million, foreign exchange rates as of September 30, 2026, and 28.6 million diluted weighted average shares outstanding.
This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after September 30, 2026.
54 boilerplate lines (safe-harbor disclaimer, contacts, call details) are set aside.

How this is scored

  • Source: the press release Medpace Holdings, Inc. filed with the SEC as Exhibit 99 to Form 8-K (Item 2.02). Financial statements and boilerplate are set aside.
  • Tone: a financial sentiment model scores each sentence 0 to 100; the release score weights sentences by how material they are.
  • Materiality and guidance: a classifier judges whether each sentence is specific information, and what the release does to the outlook.
  • New this quarter: wording that does not appear in the prior release.
  • Hedging: uncertainty words (may, could, approximately, headwinds and similar) per 100 words of narrative.

These scores describe the release's language. They are not a forecast or a recommendation. Read the original filing

Back to MEDP overview